A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

Three consecutive daily infusions of intravenous ketamine did not produce a greater antidepressant effect than the active placebo midazolam in adults aged 18–64 with treatment-resistant depression. By day 10, the ketamine group showed an average reduction of 12.55 points on the Montgomery-Åsberg Depression Rating Scale, while the midazolam group decreased by 17.22 points; by day 31, reductions were 13.73 and 12.44 points, respectively. Both treatments were well tolerated, and dissociative symptoms from ketamine were temporary. The findings indicate that this specific dosing schedule offers no notable advantage over midazolam, emphasizing the need for further research on effective treatment regimens.

Study at a glance

Abstract

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management involved a continuous 10-day infusion period with no notable adverse effects. Consequently, the primary objective of this study was to evaluate the antidepressant capacity of consecutive ketamine infusions spanning over three successive days, the duration of therapeutic response, and the overall safety profile of the treatment. In this randomized controlled trial, participants aged 18-64 with treatment-resistant depression were randomized to receive either intravenous ketamine or midazolam (used as an active placebo) for 40 min daily over three consecutive days. Statistical analysis using repeated measures ANOVA was employed to assess the changes in the total score of the Montgomery-Åsberg Depression Rating Scale (MADRS) and the clinical global impression-Severity from the initial assessment to 10 and 31 days post-infusion. Additionally, the duration of response and remission was evaluated using Kaplan-Meier survival analysis. Out of 33 randomized participants, 20 underwent the treatment as planned. By day 10th, the ketamine group had a mean reduction in MADRS score of 12.55 (95% CI = 6.70-18.09), whereas the midazolam group had a decrease of 17.22 (95% CI = 11.09-23.36). This pattern continued to day 31, with ketamine showing a mean score decrease of 13.73 (95% CI = 7.54-19.91) and midazolam a fall of 12.44 (95% CI = 5.61-19.28). Both treatments were well tolerated, with dissociative symptoms in the ketamine group being temporary and ceasing by the end of each infusion. Intravenous ketamine given for three consecutive days did not show a notable antidepressant advantage when compared to the active placebo midazolam, highlighting the need for further research into effective treatments schedules for treatment-resistant depression. NCT05026203, ClinicalTrials.gov, registered on 24/08/2021.